Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

fludarabine phosphate 19Cyclophosphamide 18Tacrolimus 17Peripheral Blood Stem Cell Transplantation 17Mycophenolic Acid 17Antilymphocyte Serum 14Busulfan 13Whole-Body Irradiation 12Methotrexate 11Cyclosporine 11Melphalan 7mogamulizumab 6Methylprednisolone 6Etoposide 6Bexarotene 6Sirolimus 5Radiotherapy 5Flow Cytometry 5Filgrastim 5sargramostim 4pembrolizumab 4Vorinostat 4Transplantation 4Therapeutics 4Rituximab 4Lenalidomide 4Brentuximab Vedotin 4Alemtuzumab 4thymoglobulin 3romidepsin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Cutaneous × Rosiglitazone × Clear all
NCT00178841 2016-02-17

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

Vanderbilt University

Phase 2 Completed
4 enrolled 5 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡